954
Views
13
CrossRef citations to date
0
Altmetric
Research Article

QSAR study of substituted 2-pyridinyl guanidines as selective urokinase-type plasminogen activator (uPA) inhibitors

, &
Pages 6-13 | Received 09 Jun 2007, Accepted 19 Oct 2007, Published online: 01 Feb 2009

References

  • K Dano, PA Andreasen, J Grondahl-Hansen, P Kristensen, LS Nielsen, and L Skriver. (1985). Plasminogen activators, tissue degradation and cancer. Adv Cancer Res 44:139–266.
  • SA Rabbani, and RHM Xing. (1998). Role of urokinase and its receptor in invasion and metastasis of hormone-dependent malignancies. Int J Oncol 12:911–920.
  • JP Irigoyen, P Munoz-Canoves, L Montero, M Koziczak, and Y Nagamine. (1999). The plasminogen activator system: Biology and regulation. Cell Mol Life Sci 56:104–132.
  • N Sidenius, and F Blasi. (2003). The urokinase plasminogen activator system in cancer. Cancer Metast Rev 22:205–222.
  • V Ellis, C Pyke, J Eriksen, H Solberg, and K Dano. (1992). The urokinase receptor: Involvement in cell surface proteolysis and cancer invasion. Ann N Y Acad Sci 667:13–31.
  • HA Chapman. (1997). Plasminogen activators, integrins, and the coordinant regulation of cell adhesion and migration. Curr Opin Cell Biol 9:714–724.
  • A Giovanni, and PF David. (2005). Protease inhibitors in the clinic. Med Chem 1:71–104.
  • A Abderrahim, K Stephanie, T Gilles, S Louis-Georges, B Pnina, G David, and AR Shafaat. (1994). Urokinase overproduction results in increased skeletal metastasis by prostate cancer cells in vivo. Cancer Res 54 (9):2372–2377.
  • GB Christopher, PD Roger, and AH Valerie. (2002). Selective urokinase-type plasminogen activator (uPA) inhibitors. Part 1: 2-Pyridinylguanidines. Bioorg Med Chem Lett 12:181–184.
  • GB Christopher, and PD Roger. (2002). Selective urokinase-type plasminogen activator (uPA) inhibitors. Part 2: (3-Substituted-5-halo-2-pyridinyl) guanidines. Bioorg Med Chem Lett 12:185–187.
  • Y Heechung, H Jack, HK Ki, and J Greer. (1990). Selective inhibition of urokinase by substituted phenylguanidines: Quantitative structure–activity relationship analyses. J Med Chem 33 (11):2956–2961.
  • AB Bhoomendra, VG Veerappa, and KG Andanappa. (2005). 3D-QSAR CoMFA studies on trypsin-like serine protease inhibitors: A comparative selectivity analysis. Bioorg Med Chem 13:2773–2782.
  • BA Bhongade, and AK Gadad. (2004). 3D-QSAR CoMFA/CoMSIA studies on urokinase plasminogen activator (uPA) inhibitors: A strategic design in novel anticancer agents. Bioorg Med Chem 12:2797–2805.
  • MOE is a molecular modeling package developed by Chemical Computing Group Inc., Canada, 2002.
  • SYSTAT 10.2 is a statistical package developed by SYSTAT software Inc, USA, 2003.
  • VALSTAT is a statistical program developed by Dr. Arun Kumar Gupta, SGSITS, Indore, 2004.
  • A Lin. J Chem Comput Group, http://www.chemcomp.com/ Journal_of_CCG/Features/descr.htm.
  • DH Cho, SK Lee, BT Kim, and KT No. (2001). Quantitative structure-activity relationship (QSAR) study of new fluorovinyloxyacetamides. Bull Korean Chem Soc 22:388–394.
  • LB Kier, and LH Hall. (1977). Structure–activity studies on hallucinogenic amphetamines using molecular connectivity. J Med Chem 20 (12):1631–1636.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.